We are live on ! Find out more
SI

Sofinnova Investments Portfolio holdings

AUM $2.63B
1-Year Est. Return 117.41%
This Fund
S&P 500
This Quarter Est. Return
+1.77%
1 Year Est. Return
+117.41%
3 Year Est. Return
+428.82%
5 Year Est. Return
+748.21%
10 Year Est. Return
–
AUM
$1.71B
AUM Growth
+$23.5M
Cap. Flow
+$140M
Cap. Flow %
8.18%
Top 10 Hldgs %
56.71%
Holding
87
New
17
Increased
22
Reduced
12
Closed
17

Top Buys

Rank Stock Value
1
RGNX icon
Regenxbio
RGNX
+$30M
2
XNCR icon
Xencor
XNCR
+$20.4M
3
BCRX icon
BioCryst Pharmaceuticals
BCRX
+$20M
4
GH icon
Guardant Health
GH
+$19.9M
5
TVTX icon
Travere Therapeutics
TVTX
+$17M

Top Sells

Rank Stock Value
1
AZN icon
AstraZeneca
AZN
+$67.8M
2
UTHR icon
United Therapeutics
UTHR
+$18.1M
3
RETA
Reata Pharmaceuticals, Inc. Class A Common Stock
RETA
+$15.8M
4
ZTS icon
Zoetis
ZTS
+$14.8M
5
EXEL icon
Exelixis
EXEL
+$10.3M

Sector Composition

Rank Sector Weight
1 Healthcare 85%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
REGN icon
76
PUT
Regeneron Pharmaceuticals
REGN
$72.9B
– –
-30,000
Closed -$18.2M
UTHR icon
77
PUT
United Therapeutics
UTHR
$26.1B
– –
-94,500
Closed -$17.4M
ZTS icon
78
Zoetis
ZTS
$32.5B
– –
-76,000
Closed -$14.8M
MRTX
79
DELISTED
Mirati Therapeutics, Inc. Common Stock
MRTX
– –
-56,900
Closed -$10.1M
RETA
80
DELISTED
Reata Pharmaceuticals, Inc. Class A Common Stock
RETA
– –
-157,488
Closed -$15.8M
ISEE
81
PUT
DELISTED
IVERIC bio, Inc. Common Stock
ISEE
– –
-255,300
Closed -$4.15M
CCXI
82
PUT
DELISTED
ChemoCentryx, Inc.
CCXI
– –
-505,800
Closed -$8.65M
XLRN
83
DELISTED
Acceleron Pharma
XLRN
– –
-39,589
Closed -$6.81M
KDMN
84
DELISTED
Kadmon Holdings, Inc.
KDMN
– –
-1,046,312
Closed -$9.11M
CTIC
85
DELISTED
CTI BioPharma Corp. (DE) Common Stock
CTIC
– –
-2,074,714
Closed -$6.12M
1 2 3
4

Similar funds

WWM
Western Wealth Management Golden, Colorado $2.63B AUM 21.3% 1-Year Est. Return
ACI
Amazon.com Inc Seattle, Washington $2.63B AUM 20.53% 1-Year Est. Return
LOAMS
Lombard Odier Asset Management (Switzerland) Petit-Lancy, Switzerland $2.63B AUM 31.52% 1-Year Est. Return
IA
Integrity Alliance Urbandale, Iowa $2.64B AUM 16.75% 1-Year Est. Return
WCA
Waratah Capital Advisors Toronto, Ontario, Canada $2.63B AUM 76.33% 1-Year Est. Return
ACM
Advance Capital Management Southfield, Michigan $2.64B AUM 13.57% 1-Year Est. Return
NIG
NFJ Investment Group Dallas, Texas $2.64B AUM 23.86% 1-Year Est. Return
WBG
Wharton Business Group Malvern, Pennsylvania $2.65B AUM 20.73% 1-Year Est. Return

Sofinnova Investments's Q4 2021 Portfolio in Review

As of Q4 2021, Sofinnova Investments held 87 positions worth $1.71B, up 1.4% from $1.69B the previous quarter. Its ten largest holdings account for 57% of the portfolio.

Sofinnova Investments deployed $140M of net new capital in Q4 2021, opening 17 new positions and adding to 22 existing holdings. Its largest new stake was Xencor: 537,030 shares worth $21.5M.

By sector, the portfolio is most concentrated in Healthcare at 85% of assets, down from 91% a quarter earlier.

On the sell side, the largest reduction was United Therapeutics, an estimated $18.1M trimmed.

  • Sofinnova Investments's largest Q4 2021 buy was Xencor: 537,030 shares worth $21.5M.
  • Sofinnova Investments added most to Regenxbio in Q4 2021, an estimated $30M increase.
  • Sofinnova Investments's biggest Q4 2021 reduction was United Therapeutics, cutting an estimated $18.1M.
  • Sofinnova Investments fully exited AstraZeneca in Q4 2021, selling an estimated $67.8M.
  • Sofinnova Investments's ten largest holdings make up 57% of its $1.71B portfolio in Q4 2021.
  • Sofinnova Investments opened 17 new positions and closed 17 in Q4 2021.
  • Sofinnova Investments's portfolio value rose 1.4% quarter-over-quarter to $1.71B.

Based on Sofinnova Investments's 13F filing for Q4 2021, filed 14 Feb 2022.